Skip to main content

Advertisement

SpringerLink
Log in

Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance

  • Transplantation (A Pileggi, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Human islet transplantation is an effective and promising therapy for type I diabetes. However, long-term insulin independence is both difficult to achieve and inconsistent. De novo or early administration of incretin-based drugs is being explored for improving islet engraftment. In addition to its glucose-dependent insulinotropic effects, incretins also lower postprandial glucose excursion by inhibiting glucagon secretion, delaying gastric emptying, and can protect beta-cell function. Incretin therapy has so far proven clinically safe and tolerable with little hypoglycemic risk. The present review aims to highlight the new frontiers in research involving incretins from both in vitro and in vivo animal studies in the field of islet transplant. It also provides an overview of the current clinical status of incretin usage in islet transplantation in the management of type I diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8.

    Article  PubMed  CAS  Google Scholar 

  2. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes. 2002;51:2148–57.

    Article  PubMed  CAS  Google Scholar 

  3. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012;35:1436–45.

    Article  PubMed  CAS  Google Scholar 

  4. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008;8:1250–61.

    Article  PubMed  CAS  Google Scholar 

  5. Alejandro R, Barton FB, Hering BJ, et al. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation. 2008;86:1783–8.

    Article  PubMed  Google Scholar 

  6. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318–30.

    Article  PubMed  CAS  Google Scholar 

  7. Ryan EA, Paty BW, Senior PA, et al. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care. 2005;28:343–7.

    Article  PubMed  Google Scholar 

  8. Danielson KK, Hatipoglu B, Kinzer K, et al. Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 Diabetes. Diabetes Care. 2013;36:450–6.

    Google Scholar 

  9. Gibly RF, Graham JG, Luo X, et al. Advancing islet transplantation: from engraftment to the immune response. Diabetologia. 2011;54:2494–505.

    Article  PubMed  CAS  Google Scholar 

  10. Shapiro AM, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation. 2005;79:1304–7.

    Article  PubMed  Google Scholar 

  11. Huang X, Moore DJ, Ketchum RJ, et al. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr Rev. 2008;29:603–30.

    Article  PubMed  CAS  Google Scholar 

  12. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.

    Article  PubMed  CAS  Google Scholar 

  13. Tanizawa Y, Kaku K. Human glucagon-like peptide-1 receptor gene in NIDDM. Nihon Rinsho. 1994;52:2731–6.

    PubMed  CAS  Google Scholar 

  14. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993;361:362–5.

    Article  PubMed  CAS  Google Scholar 

  15. Skoglund G, Hussain MA, Holz GG. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes. 2000;49:1156–64.

    Article  PubMed  CAS  Google Scholar 

  16. Baggio L, Kieffer TJ, Drucker DJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 2000;141:3703–9.

    Article  PubMed  CAS  Google Scholar 

  17. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–6.

    Article  PubMed  CAS  Google Scholar 

  18. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741–8.

    Article  PubMed  CAS  Google Scholar 

  19. van der Burg MP, van Suylichem PT, Guicherit OR, et al. Glucoregulation after canine islet transplantation: contribution of insulin secretory capacity, insulin action, and the entero-insular axis. Cell Transplant. 1997;6:497–503.

    Article  PubMed  Google Scholar 

  20. van der Burg MP, van Suylichem PT, Guicherit OR, et al. The relative contribution of insulin secretory capacity, insulin action, and incretins to metabolic control after islet transplantation in dogs. J Mol Med. 1999;77:104–6.

    Article  PubMed  Google Scholar 

  21. King A, Lock J, Xu G, et al. Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia. 2005;48:2074–9.

    Article  PubMed  CAS  Google Scholar 

  22. • Toyoda K, Okitsu T, Yamane S, et al. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun. 2008;367:793–8. The study reports a beneficial effect of GLP-1 in restoration of normoglycemia in a minimal transplant rodent model and also indicated the benefits were achieved via reduction the number of apoptotic beta-cells during early post-transplant phase.

    Article  PubMed  CAS  Google Scholar 

  23. Sharma A, Sorenby A, Wernerson A, et al. Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. Diabetologia. 2006;49:1247–53.

    Article  PubMed  CAS  Google Scholar 

  24. • Juang JH, Kuo CH, Wu CH, et al. Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets. Cell Transplant. 2008;17:641–7. This study reports in vivo islet graft function improvement by exendin-4 in a marginal number rodent transplant model with higher cure rate and shorter time to reach normoglycemia.

    Article  PubMed  Google Scholar 

  25. •• Jia X, Sharma A, Kumagai-Braesch M, et al. Exendin-4 increases the expression of hypoxia-inducible factor-1alpha in rat islets and preserves the endocrine cell volume of both free and macroencapsulated islet grafts. Cell Transplant. 2012;21:1269–83. The study links the beneficial effect of GLP-1 with increased levels of HIF-1a mRNA and protein expression, indicating that GLP-1 improves islet graft resistance to hypoxia peri-transplant period by increasing HIF-1a.

    Article  PubMed  Google Scholar 

  26. •• Buss JL, Rajab A, Essig ED, et al. Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared with treatment after transplant only. J Transplant. 2012;2012: 382518. This study reports in monkey transplant model that exendin-4 treatment prior to transplant has more beneficial effects on islet graft function than post-transplant treatment.

    PubMed  Google Scholar 

  27. •• Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 2008;17:631–40. This study shows that combination therapy with GLP-1 and gastrin expands the beta-cell mass in human islets implanted in NOD mice, largely from pancreatic duct cells associated within the islets and improves islet graft function.

    Article  PubMed  Google Scholar 

  28. •• Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 2008;57:3281–8. This report shows that combination therapy with GLP-1 and gastrin restores normoglycemia in diabetic NOD mice by increasing insulin-positive cells, reducing beta-cell apoptosis, and down-regulating the autoimmune response.

    Article  PubMed  CAS  Google Scholar 

  29. Suen PM, Li K, Chan JC, et al. In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice. Int J Biochem Cell Biol. 2006;38:951–60.

    Article  PubMed  CAS  Google Scholar 

  30. Hardikar AA, Wang XY, Williams LJ, et al. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology. 2002;143:3505–14.

    Article  PubMed  CAS  Google Scholar 

  31. Mancuso F, Basta G, Calvitti M, et al. Long-term cultured neonatal porcine islet cell monolayers: a potential tissue source for transplant in diabetes. Xenotransplantation. 2006;13:289–98.

    Article  PubMed  Google Scholar 

  32. Movassat J, Beattie GM, Lopez AD, et al. Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab. 2002;87:4775–81.

    Article  PubMed  CAS  Google Scholar 

  33. •• Tian L, Gao J, Weng G, et al. Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts. Transpl Int. 2011;24:856–64. This study shows that under exendin-4 treatment, mouse islet grafts have more beta-cell proliferation than human islet grafts. In human islet grafts, extent of beta-cell proliferation is dependent on donor age.

    Article  PubMed  CAS  Google Scholar 

  34. Gao J, Tian L, Weng G, et al. Stimulating beta-cell replication and improving islet graft function by AR231453, A gpr119 agonist. Transplant Proc. 2011;43:3217–20.

    Article  PubMed  CAS  Google Scholar 

  35. Barlow AD, Xie J, Moore CE, et al. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia. 2012;55:1355–65.

    Article  PubMed  CAS  Google Scholar 

  36. Tanemura M, Ohmura Y, Deguchi T, et al. Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. Am J Transplant. 2012;12:102–14.

    Article  PubMed  CAS  Google Scholar 

  37. Johnson JD, Ao Z, Ao P, et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant. 2009;18:833–45.

    Article  PubMed  Google Scholar 

  38. D'Amico E, Hui H, Khoury N, et al. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. J Mol Endocrinol. 2005;34:377–90.

    Article  PubMed  Google Scholar 

  39. Aoki T, Hui H, Umehara Y, et al. Intrasplenic transplantation of encapsulated genetically engineered mouse insulinoma cells reverses streptozotocin-induced diabetes in rats. Cell Transplant. 2005;14:411–21.

    Article  PubMed  Google Scholar 

  40. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem. 2010;285:40050–9.

    Article  PubMed  CAS  Google Scholar 

  41. •• Cechin SR, Perez-Alvarez I, Fenjves E, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant. 2012;21:633–48. This report describes anti-inflammatory and cytoprotective properties of exendin-4 in human islets by reducing tissue factor, IFN- γ, IL-17, IL-1β, IL-2, caspase 3 activation, whereas increased phosphorylation of ERK1/2, STAT3, and Akt. Also induction of serine proteinase inhibitor 9 (PI-9) was detected.

  42. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 2007;148:5136–44.

    Article  PubMed  CAS  Google Scholar 

  43. Ogawa N, List JF, Habener JF, et al. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes. 2004;53:1700–5.

    Article  PubMed  CAS  Google Scholar 

  44. Tian B, Hao J, Zhang Y, et al. Upregulating CD4 + CD25 + FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation. 2009;87:198–206.

    Article  PubMed  CAS  Google Scholar 

  45. Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology. 2010;151:3049–60.

    Article  PubMed  CAS  Google Scholar 

  46. Zhang J, Tokui Y, Yamagata K, et al. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia. 2007;50:1900–9.

    Article  PubMed  CAS  Google Scholar 

  47. Wideman RD, Yu IL, Webber TD, et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci U S A. 2006;103:13468–73.

    Article  PubMed  CAS  Google Scholar 

  48. Wideman RD, Covey SD, Webb GC, et al. A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes. 2007;56:2744–52.

    Article  PubMed  CAS  Google Scholar 

  49. • Chae HY, Kang JG, Kim CS, et al. Effect of glucagon-like peptide-1 gene expression on graft function in mouse islet transplantation. Transpl Int. 2012;25:242–9. The study shows that delivery of the GLP-1 gene using adenovirus to islets enhances islet cell survival during the early post-transplant period and preserves islet mass and graft functions with marginal mass transplant model.

    Article  PubMed  CAS  Google Scholar 

  50. •• Merani S, Truong W, Emamaullee JA, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology. 2008;149:4322–8. This report demonstrates that liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose-dependent insulin secretion and has a beneficial impact on the engraftment and function of syngeneic islet transplants in mice, especially in early administration.

    Article  PubMed  CAS  Google Scholar 

  51. •• Emamaullee JA, Merani S, Toso C, et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology. 2009;150:2145–52. This study shows that incubation with liraglutide enhanced porcine islet survival and function after prolonged culture. Although no improvement of insulin independence rate, liraglutide significant increases in insulin secretion and acute-phase insulin response.

    Article  PubMed  CAS  Google Scholar 

  52. • Toso C, McCall M, Emamaullee J, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int. 2010;23:259–65. The report demonstrates that human islets cultured with liraglutide increases islet mass, especially for large islets and reduces beta-cell apoptosis. In vivo continuous administration of liraglutide warrants long-term graft function.

    Article  PubMed  CAS  Google Scholar 

  53. •• Kim SJ, Nian C, Doudet DJ, et al. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes. 2008;57:1331–9. This study shows that sitagliptin, a DPP-IV inhibitor, prolongs islet graft survival in an animal model of type I diabetes associated with a profound protective effect on islet sizes.

    Article  PubMed  CAS  Google Scholar 

  54. •• Kim SJ, Nian C, Doudet DJ, et al. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009;58:641–51. This study shows that sitagliptin treatment results a prolonged graft function of the transplanted islets in diabetic NOD mice, especially applied prior to early administration and sitagliptin reduces insulitis in NOD mice by decreasing the homing of CD4+ T-cells into pancreatic beta-cells involving cAMP/PKA/RAC1 activation.

    Article  PubMed  CAS  Google Scholar 

  55. • Kim YS, Oh SH, Park KS, et al. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin. Pancreas. 2011;40:855–60. This report shows that DPP-4 inhibitor favorably affects islet transplant outcomes in partially pancreatectomized diabetic mice by increasing beta-cell proliferation and inhibition beta-cell apoptosis.

    Article  PubMed  CAS  Google Scholar 

  56. Reiner T, Thurber G, Gaglia J, et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A. 2011;108:12815–20.

    Article  PubMed  CAS  Google Scholar 

  57. Wu Z, Todorov I, Li L, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor. Bioconjug Chem. 2011;22:1587–94.

    Article  PubMed  CAS  Google Scholar 

  58. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010;363:1289–90.

    Article  PubMed  Google Scholar 

  59. Connolly BM, Vanko A, McQuade P, et al. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist. Mol Imaging Biol. 2012;14:79–87.

    Article  PubMed  Google Scholar 

  60. Fung M, Thompson D, Shapiro RJ, et al. Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes. Diabetes Res Clin Pract. 2006;74:189–93.

    Article  PubMed  CAS  Google Scholar 

  61. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83:24–8.

    Article  PubMed  Google Scholar 

  62. •• Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008;86:1658–65. This clinical study shows that application of exendin-4 in islet transplant patients who lost graft function and insulin independence helps the restoration of islet graft function. Also exendin-4 improves first and second phase insulin release in response to glucose challenge and suppresses postprandial hyperglycemia.

    Article  PubMed  Google Scholar 

  63. •• Rickels MR, Mueller R, Markmann JF, et al. Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009;94:181–9. This clinical study shows that in both islet and pancreas transplant patients, GLP-1 induces enhancement of glucose-dependent insulin secretion, but not glucagon suppression and the effect is depend on the functional beta-cell mass.

    Article  PubMed  CAS  Google Scholar 

  64. • Tharavanij T, Betancourt A, Messinger S, et al. Improved long-term health-related quality of life after islet transplantation. Transplantation. 2008;86:1161–7. This retrospective clinical survey indicates that exendin-4 has positive effects on mental health and health perception scales of HSQ 2.0 of islet transplant patients regardless of islet infusion number, islet alone, or islet after kidney transplantation.

    Article  PubMed  Google Scholar 

  65. Kwon G, Marshall CA, Pappan KL, et al. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes. 2004;53 Suppl 3:S225–32.

    Article  PubMed  CAS  Google Scholar 

  66. •• Van de Velde S, Hogan MF, Montminy M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci U S A. 2011;108:16876–82. Although unrelated to islet transplantation, this study demonstrates that GLP-1 promotes islet viability by activating mTOR pathway and accumulation of HIF-1a. Rapamycin, a common immunosuppressant used for islet transplant, disrupts GLP-1 beneficial effects on beta cell and may explain lacking long-term trophic effect of GLP-1 in clinical setting.

    Article  PubMed  Google Scholar 

  67. •• Velmurugan K, Balamurugan AN, Loganathan G, et al. Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB. Endocrinology. 2012;153:1116–28. This study shows that a combination of exendin-4 and overexpression of viral CREB exerted enhanced antiapoptotic action in cultured islets against hypoxia and cytokines. More significantly, transplantation of human islets transduced with adenoviral CREB and treated with exendin-4 showed improved glycemic control over a 30-d period in diabetic athymic nude mice. These observations have significant implications in the therapeutic potential of exendin-4 and CREB in the islet transplantation setting as well as in preserving β-cell mass of diabetic patients.

    Article  PubMed  CAS  Google Scholar 

  68. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009;106:1285–90.

    Article  PubMed  CAS  Google Scholar 

  69. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care. 2006;29:471.

    Article  PubMed  Google Scholar 

  70. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med. 2008;358:1969–70. discussion 1971–1962.

    Article  PubMed  CAS  Google Scholar 

  71. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–6.

    Article  PubMed  CAS  Google Scholar 

  72. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97:121–31.

    Article  PubMed  CAS  Google Scholar 

  73. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–86.

    Article  PubMed  Google Scholar 

  74. Tatarkiewicz K, Belanger P, Gu G, et al. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab. 2013;15:417–26

    Google Scholar 

  75. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98:271–84.

    Article  PubMed  CAS  Google Scholar 

  76. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for Glucagon-producing Neuroendocrine Tumors. Diabetes. 2013;62:2595–604.

    Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Chicago Diabetes Project (CDP) and a start up grant by University of Illinois at Chicago College Medicine (JO).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Yong Wang declares that he has no conflict of interest. Meirigeng Qi declares that he has no conflict of interest. James J. McGarrigle declares that he has no conflict of interest. Brian Rady declares that he has no conflict of interest. Maureen E. Davis declares that she has no conflict of interest. Pilar Vaca declares that she has no conflict of interest. Jose Oberholzer declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Surgery/Transplant, University of Illinois at Chicago, Chicago, IL, 60612, USA

    Yong Wang, Meirigeng Qi, James J. McGarrigle, Brian Rady, Maureen E. Davis, Pilar Vaca & Jose Oberholzer

Authors
  1. Yong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meirigeng Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James J. McGarrigle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian Rady
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maureen E. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pilar Vaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jose Oberholzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose Oberholzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Y., Qi, M., McGarrigle, J.J. et al. Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance. Curr Diab Rep 13, 723–732 (2013). https://doi.org/10.1007/s11892-013-0402-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-013-0402-z

Keywords

Search

Navigation